Gujarat Themis Biosyn bets ₹1,300 cr to buy Japan's MicroBiopharm
The deal is valued at 33% of the company's market cap and aims to shift its focus from intermediates to high-tech CDMO services.
What's new
- Gujarat Themis Biosyn is buying 100% of Japanese CDMO MicroBiopharm for ¥21.5bn.
- The target generated ₹570 cr in revenue last year, potentially doubling the buyer's top line.
- The acquisition adds precision fermentation and plasmid DNA manufacturing to the buyer’s portfolio.
Why it matters
This deal is massive relative to the buyer's ₹3,891 cr market valuation. It forces a change in the company's identity from a local manufacturer of fermentation intermediates to a specialized player in oncology APIs and gene-therapy components.
What we're watching
- Regulatory clearance from Japanese authorities.
- The integration of Japanese high-tech manufacturing with Indian cost structures.
- Pro-forma debt levels following the ₹1,300 cr cash outflow.
The full read
Gujarat Themis Biosyn is jumping from a domestic intermediate manufacturer to a global player with the acquisition of MicroBiopharm Japan. At ₹1,300 crore, the price tag is one-third of the company's entire market capitalization.
It is a massive bet.
MicroBiopharm brings established operations in fermentation, oncology APIs, and plasmid DNA, which marks a major technological leap from the buyer’s current setup. The move promises to nearly double its annual revenue, based on the target's reported ₹570 crore turnover, fundamentally altering the firm's growth trajectory and its technical standing in the international life-sciences market. The deal is set to close in the second quarter of FY2027, provided Japanese regulators approve. What changes from here is whether the company can successfully digest a foreign firm of this size and complexity without stretching its balance sheet too thin.